Aclaris Therapeutics (FRA:8AT) Other Long Term Assets : €3.68 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Aclaris Therapeutics Other Long Term Assets?

Aclaris Therapeutics's other long-term assets for the quarter that ended in Mar. 2024 was €3.68 Mil.

Aclaris Therapeutics's quarterly other long-term assets increased from Sep. 2023 (€2.49 Mil) to Dec. 2023 (€3.57 Mil) and increased from Dec. 2023 (€3.57 Mil) to Mar. 2024 (€3.68 Mil).

Aclaris Therapeutics's annual other long-term assets declined from Dec. 2021 (€3.15 Mil) to Dec. 2022 (€2.58 Mil) but then increased from Dec. 2022 (€2.58 Mil) to Dec. 2023 (€3.57 Mil).

Aclaris Therapeutics Other Long Term Assets Historical Data

The historical data trend for Aclaris Therapeutics's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclaris Therapeutics Other Long Term Assets Chart

Aclaris Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long Term Assets

Get a 7-Day Free Trial

4.34

3.71

3.15

2.58

3.57

Aclaris Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Long Term Assets	Get a 7-Day Free Trial															3.06	2.66	2.49	3.57	3.68

Aclaris Therapeutics Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Aclaris Therapeutics (FRA:8AT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (FRA:8AT) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

ACRS:USA

Address

640 Lee Road, Suite 200, Wayne, PA, USA, 19087

Website

https://www.aclaristx.com

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Aclaris Therapeutics (FRA:8AT) Headlines

No Headlines